Liquid biopsies that detect circulating tumour DNA (ctDNA) have the potential to
revolutionise the personalised management of colorectal cancer. For patients with early …

Circulating cell free tumour DNA (ctDNA) maintains the same genomic alterations that are
present in the corresponding tumour, thereby allowing for quantitative and qualitative real …

Liquid biopsy is a minimally invasive approach to obtain circulating materials that originate
from tumor cells through the sampling of body fluids, mainly peripheral blood. Because of its …

Background For patients with metastatic colorectal cancer, stratification for treatment
(surgery or chemotherapy) is often based on crude clinicopathological characteristics like …

Colorectal cancer (CRC) is frequently diagnosed at an advanced stage of the disease, the
pathogenesis of which is influenced by genetic and epigenetic events. Circulating tumor …

There exists a tremendous opportunity in identifying and determining the appropriate
predictive and prognostic biomarker (s) for risk stratification of patients with colorectal …

Circulating tumor DNA (ctDNA) is a component of cell-free DNA (cfDNA) that is shed by
malignant tumors into the bloodstream and other bodily fluids. ctDNA can comprise up to …

Background Increasingly, circulating tumor DNA (ctDNA) is proposed as a tool for minimal
residual disease (MRD) assessment. Digital PCR (dPCR) offers low analysis costs and …

Background ctDNA has been recently suggested as a major prognostic factor in resected
stage II and III colon cancer patients (pts) 1, 2. Its predictive value for adjuvant treatment …

Introduction Colorectal cancer (CRC) is a highly prevalent disease, wherein,~ 30%–40% of
patients with CRC relapse postresection. In some patients with CRC, adjuvant …